The FDA said today that Insulet (NSDQ:PODD) last month recalled 18 lots of its flagship OmniPod insulin management system due to a needle deployment issue.
No serious injuries or deaths were reported as a result of the problem, revealed by a slight increase in reports of failed or delayed needle deployment. The reported incidence is 1% to 2%, the federal safety watchdog said. Insulet notified customers Nov. 2, the FDA said.
